What Patients Need to Know Side effects: Similar to other GLP-1 drugsmostly nausea, vomiting, or digestive upset
A monthly expense of $200$350 still translates to $2,400$4,200 per year a sharp drop from previous annual costs exceeding $12,000, but still far from affordable for many Americans
Generally, the safety profile improves through proper dose titration, beginning at lower doses and gradually increasing based on response and tolerability
Bimagrumab: Reducing fat and retaining muscle Bimagrumab, a drug developed by Eli Lilly, aims to help those taking it reduce fat whilst retaining muscle
The Phase 3 program is expected to further characterize the optimal escalation protocol for potential regulatory submission
Severe cases may cause fainting (syncope), which requires immediate medical evaluation